Antiretroviral medication for preventing HIV infection in nonoccupational settings.
作者信息
Bogoch Isaac I, Scully Eileen P, Zachary Kimon C
机构信息
Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ont.
出版信息
CMAJ. 2012 Jul 10;184(10):1153-7. doi: 10.1503/cmaj.120267. Epub 2012 May 28.
Abstract
摘要
相似文献
1
Antiretroviral medication for preventing HIV infection in nonoccupational settings.
CMAJ. 2012 Jul 10;184(10):1153-7. doi: 10.1503/cmaj.120267. Epub 2012 May 28.
2
[Post-exposure HIV prevention within and outside the hospital].
Ther Umsch. 1998 May;55(5):289-94.
3
Human immunodeficiency virus postexposure prophylaxis for adolescents and children.
Pediatrics. 2001 Aug;108(2):E38. doi: 10.1542/peds.108.2.e38.
4
Post-exposure prophylaxis for HIV infection.
Expert Rev Anti Infect Ther. 2011 Apr;9(4):431-42. doi: 10.1586/eri.11.20.
5
Nonoccupational HIV postexposure prophylaxis.
JAMA. 2005 Oct 5;294(13):1615; author reply 1615-6. doi: 10.1001/jama.294.13.1615-a.
6
Seroconversion following nonoccupational postexposure prophylaxis against HIV.
Clin Infect Dis. 2005 Nov 15;41(10):1507-13. doi: 10.1086/497268. Epub 2005 Oct 13.
7
New guidelines for antiretroviral therapy in nonoccupational postexposure prophylaxis.
AIDS Clin Care. 2005 Mar;17(3):22.
8
HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy.
J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Feb 1;20(2):208-9. doi: 10.1097/00042560-199902010-00016.
9
Recommendations for the use of antiretroviral drugs in pregnant women infected with HIV.
Am Fam Physician. 1998 Jul;58(1):261-3.
10
Unintended HIV-1 Infection During Analytical Therapy Interruption.
J Infect Dis. 2020 Apr 27;221(10):1740-1742. doi: 10.1093/infdis/jiz611.
引用本文的文献
1
[Not Available].
Can Fam Physician. 2019 Apr;65(4):e145-e146.
2
HIV preexposure prophylaxis in Canadian primary care and community settings.
Can Fam Physician. 2019 Apr;65(4):271-272.
本文引用的文献
1
Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):354-9. doi: 10.1097/QAI.0b013e31824a03b8.
2
Prevention of HIV-1 infection with early antiretroviral therapy.
N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.
3
Antiretrovirals for HIV prevention: translating promise into praxis.
Lancet. 2011 Jul 16;378(9787):206-8. doi: 10.1016/S0140-6736(11)61056-8.
4
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):65-8.
5
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.
6
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19.
7
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.
JAMA. 2010 Jul 21;304(3):321-33. doi: 10.1001/jama.2010.1004.
8
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.
Lancet. 2009 Jan 3;373(9657):48-57. doi: 10.1016/S0140-6736(08)61697-9. Epub 2008 Nov 27.
9
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):494-9. doi: 10.1097/QAI.0b013e318162afcb.
10
Seroconversion following nonoccupational postexposure prophylaxis against HIV.
Clin Infect Dis. 2005 Nov 15;41(10):1507-13. doi: 10.1086/497268. Epub 2005 Oct 13.
Zotero 插件